FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149898816> ?p ?o ?g. }

• W2149898816 endingPage "64" @default.
• W2149898816 startingPage "57" @default.
• W2149898816 abstract "The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep molecular response (MR4 (BCR-ABL1⩽0.01% on the International Scale or undetectable BCR-ABL1 with ⩾10 000 ABL1 transcripts)) at 18 months was evaluated as the primary end point, with molecular responses monitored by the European Treatment and Outcome Study network of standardized laboratories. This analysis was conducted after all patients had completed 24 months of study treatment (80.9% of patients) or discontinued early. In patients with typical BCR-ABL1 transcripts and ⩽3 months of prior imatinib therapy, 38.4% (404/1052) achieved MR4 at 18 months. Six patients (0.6%) developed accelerated or blastic phase, and 13 (1.2%) died. The safety profile of nilotinib was consistent with that of previous studies, although the frequencies of some nilotinib-associated adverse events were lower (for example, rash, 21.4%). Ischemic cardiovascular events occurred in 6.0% of patients. Routine monitoring of lipid and glucose levels was not mandated in the protocol. These results support the use of frontline nilotinib, particularly when achievement of a deep molecular response (a prerequisite for attempting treatment-free remission in clinical trials) is a treatment goal." @default.
• W2149898816 created "2016-06-24" @default.
• W2149898816 creator A5009003698 @default.
• W2149898816 creator A5009358618 @default.
• W2149898816 creator A5011977231 @default.
• W2149898816 creator A5016053923 @default.
• W2149898816 creator A5018592613 @default.
• W2149898816 creator A5018757544 @default.
• W2149898816 creator A5019949455 @default.
• W2149898816 creator A5026075651 @default.
• W2149898816 creator A5032509163 @default.
• W2149898816 creator A5035964802 @default.
• W2149898816 creator A5036839901 @default.
• W2149898816 creator A5038582279 @default.
• W2149898816 creator A5044224344 @default.
• W2149898816 creator A5047688718 @default.
• W2149898816 creator A5050873337 @default.
• W2149898816 creator A5055797334 @default.
• W2149898816 creator A5056580422 @default.
• W2149898816 creator A5059251853 @default.
• W2149898816 creator A5061299820 @default.
• W2149898816 creator A5068067485 @default.
• W2149898816 creator A5074486986 @default.
• W2149898816 creator A5075222101 @default.
• W2149898816 creator A5077725308 @default.
• W2149898816 creator A5085721454 @default.
• W2149898816 creator A5087934925 @default.
• W2149898816 date "2015-10-06" @default.
• W2149898816 modified "2023-10-15" @default.
• W2149898816 title "Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study" @default.
• W2149898816 cites W1924236513 @default.
• W2149898816 cites W1968747503 @default.
• W2149898816 cites W1985283276 @default.
• W2149898816 cites W1998406030 @default.
• W2149898816 cites W2009972868 @default.
• W2149898816 cites W2011814974 @default.
• W2149898816 cites W2019633460 @default.
• W2149898816 cites W2028669471 @default.
• W2149898816 cites W2050904392 @default.
• W2149898816 cites W2058216377 @default.
• W2149898816 cites W2061440903 @default.
• W2149898816 cites W2064367288 @default.
• W2149898816 cites W2072703295 @default.
• W2149898816 cites W2072834954 @default.
• W2149898816 cites W2074301005 @default.
• W2149898816 cites W2077812841 @default.
• W2149898816 cites W2101513023 @default.
• W2149898816 cites W2105783133 @default.
• W2149898816 cites W2106266094 @default.
• W2149898816 cites W2112810605 @default.
• W2149898816 cites W2117356576 @default.
• W2149898816 cites W2119424308 @default.
• W2149898816 cites W2124097332 @default.
• W2149898816 cites W2143939343 @default.
• W2149898816 cites W2154748904 @default.
• W2149898816 cites W2160000537 @default.
• W2149898816 cites W2597789345 @default.
• W2149898816 cites W2980034313 @default.
• W2149898816 cites W648499296 @default.
• W2149898816 doi "https://doi.org/10.1038/leu.2015.270" @default.
• W2149898816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4705425" @default.
• W2149898816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26437782" @default.
• W2149898816 hasPublicationYear "2015" @default.
• W2149898816 type Work @default.
• W2149898816 sameAs 2149898816 @default.
• W2149898816 citedByCount "87" @default.
• W2149898816 countsByYear W21498988162016 @default.
• W2149898816 countsByYear W21498988162017 @default.
• W2149898816 countsByYear W21498988162018 @default.
• W2149898816 countsByYear W21498988162019 @default.
• W2149898816 countsByYear W21498988162020 @default.
• W2149898816 countsByYear W21498988162021 @default.
• W2149898816 countsByYear W21498988162022 @default.
• W2149898816 countsByYear W21498988162023 @default.
• W2149898816 crossrefType "journal-article" @default.
• W2149898816 hasAuthorship W2149898816A5009003698 @default.
• W2149898816 hasAuthorship W2149898816A5009358618 @default.
• W2149898816 hasAuthorship W2149898816A5011977231 @default.
• W2149898816 hasAuthorship W2149898816A5016053923 @default.
• W2149898816 hasAuthorship W2149898816A5018592613 @default.
• W2149898816 hasAuthorship W2149898816A5018757544 @default.
• W2149898816 hasAuthorship W2149898816A5019949455 @default.
• W2149898816 hasAuthorship W2149898816A5026075651 @default.
• W2149898816 hasAuthorship W2149898816A5032509163 @default.
• W2149898816 hasAuthorship W2149898816A5035964802 @default.
• W2149898816 hasAuthorship W2149898816A5036839901 @default.
• W2149898816 hasAuthorship W2149898816A5038582279 @default.
• W2149898816 hasAuthorship W2149898816A5044224344 @default.
• W2149898816 hasAuthorship W2149898816A5047688718 @default.
• W2149898816 hasAuthorship W2149898816A5050873337 @default.
• W2149898816 hasAuthorship W2149898816A5055797334 @default.
• W2149898816 hasAuthorship W2149898816A5056580422 @default.
• W2149898816 hasAuthorship W2149898816A5059251853 @default.
• W2149898816 hasAuthorship W2149898816A5061299820 @default.
• W2149898816 hasAuthorship W2149898816A5068067485 @default.
• W2149898816 hasAuthorship W2149898816A5074486986 @default.
• W2149898816 hasAuthorship W2149898816A5075222101 @default.
• W2149898816 hasAuthorship W2149898816A5077725308 @default.

• next